Press Releases XOMA Royalty Corporation Nasdaq

Equities

XOMAP

US98419J3059

Market Closed - Nasdaq Other stock markets 04:30:01 2024-07-11 pm EDT			5-day change	1st Jan Change
25.4 ^USD	-0.78%		-3.57%	-0.04%

Jul. 09	Xoma Changes Name to Xoma Royalty	MT
Jul. 01	XOMA Corporation(NasdaqGM:XOMA) added to Russell 3000 Growth Index	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

XOMA Declares Quarterly Preferred Stock Dividends	Jun. 20	AQ
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals Sale of its Priority Review Voucher	Jun. 13	AQ
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher	Jun. 12	AQ
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	May. 14	AQ
Xoma: Q1 Earnings Snapshot	May. 09	AQ
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	May. 09	AQ
XOMA : 2024 Letter to Shareholders	May. 09	PU
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	Apr. 30	AQ
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	Apr. 25	AQ
XOMA : Acquisition/Asset Disposal - Form 8-K	Apr. 03	PU
XOMA Corporation Announces Closing of Tender Offer	Apr. 03	AQ
XOMA Declares Quarterly Preferred Stock Dividends	Mar. 21	AQ
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	Mar. 19	AQ
Xoma: Q4 Earnings Snapshot	Mar. 08	AQ
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	Mar. 08	AQ
XOMA to Present at Upcoming Investor Conferences in March	Feb. 28	AQ
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	Feb. 19	AQ
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	Feb. 16	PR
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	Feb. 16	AQ
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	Jan. 19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases XOMA Royalty Corporation Nasdaq

Equities

XOMAP

US98419J3059

Press Releases

Filters